12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GLPG0634: Phase IIb started

Galapagos began the double-blind, dose-escalation, international Phase IIb DARWIN 1 and DARWIN 2 trials of oral GLPG0634 in RA patients with inadequate response to methotrexate. DARWIN 1 will enroll 595 patients, who will receive 50, 100 or 200 mg once-daily GLPG0634 plus methotrexate; 25, 50 or 100 mg twice-daily GLPG0634 plus methotrexate; or placebo plus methotrexate for 24 weeks. DARWIN...

Read the full 279 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >